Aurobindo Pharma receives warning from SEBI for non-disclosures related to USFDA audit

The market regulator, in its letter to Aurobindo Pharma dated June 24, said the company had disclosed very limited and restricted information related to the inspection. The only fact disclosed by the company was that a warning letter was received from USFDA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BHK3bTi
via IFTTT